ARTICLE | Product Development

Innate's KIR royale

BMS adds immunotherapy arm with Innate's anti-KIR mAb for cancer

July 11, 2011 7:00 AM UTC

With a product on the market that harnesses the adaptive immune system to attack cancer, Bristol-Myers Squibb Co. made its first move into the innate immunology space by licensing a mAb from Innate Pharma S.A. that stimulates NK cell activity.

The candidate, IPH 2102, is in a Phase I trial for acute myelogenous leukemia...